Related Experiment Video
Updated: Mar 22, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Glibenclamide-induced profound hypoglycaemic crisis: a case report
Arshad Hussain1, Iftikhar Ali2, Aziz Ullah Khan2
1Department of Medicine and Allied, Northwest General Hospital and Research Centre, Peshawar, Khyber Pakhtunkhwa, Pakistan.
Therapeutic Advances in Endocrinology and Metabolism
|April 20, 2016
Summary
Sulfonylureas, used for type II diabetes, carry risks like hypoglycemia. This case highlights the severe complications of these oral antidiabetic drugs, emphasizing careful patient evaluation.
Area of Science:
- Endocrinology
- Pharmacology
- Internal Medicine
Background:
- The long-term efficacy of sulfonylureas for type II diabetes is debated.
- Antidiabetic drug benefits must be balanced against adverse effects, particularly hypoglycemia.
- Hypoglycemia is a significant, often underreported complication of oral hypoglycemic agents.
Purpose of the Study:
- To present a case of severe drug-induced hypoglycemia.
- To underscore the risks associated with sulfonylurea use in type II diabetes.
- To emphasize the importance of patient evaluation and counseling.
Main Methods:
- Case report of a 77-year-old male with type II diabetes, hypertension, and renal disease.
- Presentation with symptoms including fever, diarrhea, and altered mental status.
- Diagnosis of hypoglycemia (blood sugar 45 mg/dl) and management with IV dextrose.
Main Results:
- The patient experienced severe hypoglycemia with significant neurological impairment.
- The event was attributed to sulfonylurea medication.
- Prompt management with intravenous dextrose led to recovery.
Conclusions:
- Drug-induced hypoglycemia is a serious adverse event associated with sulfonylureas.
- Thorough patient assessment and counseling are crucial to mitigate risks.
- Underreporting of hypoglycemia as a complication of oral antidiabetic agents needs addressing.
More Related Videos
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
926
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
926
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
912
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
912
01:23Dipeptidyl Peptidase 4 Inhibitors
986
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
986
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.6K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.6K